Find out more about Tom John's experience
Tom John's highlights
FEATURED Journal article
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinicsRead more
Tom John's selected work
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged..
Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Canc..
Application of a risk-management framework for integration of stromal tumor-infiltrating l..
Australian consensus statement for best practice ROS1 testing in advanced non-small cell l..
Displaying the 36 most recent scholarly works by Tom John.
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics
B Meiser, R Kaur, J Kirk, A Morrow, M Peate, WKT Wong, E McPike, E Cops, C Dowson, R Austin, M Fine, L Thrupp, R Ward, F Macrae, JE Hiller, AH Trainer, G Mitchell
Journal article | 2020 | Familial Cancer
INTRODUCTION: This nationwide study assessed the impact of Lynch syndrome-related risk management guidelines on clinicians' recomm..
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
Marliese Alexander, Nick Pavlakis, Thomas John, Rachel O'Connell, Steven Kao, Brett GM Hughes, Adrian Lee, Sarah A Hayes, Viive M Howell, Stephen J Clarke, Michael Millward, Kate Burbury, Benjamin Solomon, Malinda Itchins
Journal article | 2020 | Lung Cancer
OBJECTIVES: This study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and..
Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report
Ashray Gunjur, Geoff Chong, Adeline Lim, Eddie Lau, Paul Mitchell, Thomas John, Surein Arulananda
Journal article | 2020 | Clinical Lung Cancer
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Jan Hudeček, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker, Jose van den Berg, Koen K van de Vijver, Karolina Sikorska, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O Nielsen, Sunil S Badve, Stefan Michiels, William Fraser Symmans, Christos Sotiriou, David L Rimm, Stephen M Hewitt, Carsten Denkert, Sibylle Loibl, et al.
Journal article | 2020 | npj Breast Cancer
Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic tripl..
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer
Na Li, Simone McInerny, Magnus Zethoven, Dane Cheasley, Belle WX Lim, Simone M Rowley, Lisa Devereux, Norah Grewal, Somayeh Ahmadloo, David Byrne, Jue Er Amanda Lee, Jason Li, Stephen B Fox, Thomas John, Yoland Antill, Kylie L Gorringe, Paul A James, Ian G Campbell
Journal article | 2019 | JNCI: Journal of the National Cancer Institute
BACKGROUND: Loss-of-function variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast can..
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer
Nick Pavlakis, Caroline Cooper, Thomas John, Steven Kao, Sonja Klebe, Chee Khoon Lee, Trishe Leong, Michael Millward, Ken O'Byrne, Prudence A Russell, Benjamin Solomon, Wendy A Cooper, Stephen Fox
Journal article | 2019 | Pathology
Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced n..
Uptake of polygenic risk information among women at potentially high breast cancer risk
T Yanes, B Meiser, R Kaur, M Scheepers-Joynt, M Young, K Barlow-Stewart, T John, M Harris, Y Antill, J Halliday, J Burke, T Roscioli, P Mitchell, P James
Conference Proceedings | 2019 | EUROPEAN JOURNAL OF HUMAN GENETICS
Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
Surein Arulananda, Hongdo Do, Gareth Rivalland, Zoe Loh, Ashan Musafer, Eddie Lau, Paul Mitchell, Alexander Dobrovic, Thomas John
Journal article | 2019 | Journal of Thoracic Disease
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F Lee, Tiffany J Harris, Sharon Tran, Marco Evangelista, Surein Arulananda, Thomas John, Celeste Ramnac, Chloe Hobbs, Haoran Zhu, Gency Gunasingh, David Segal, Andreas Behren, Jonathan Cebon, Alexander Dobrovic, John M Mariadason, Andreas Strasser, Leona Rohrbeck, Nikolas K Haass, Marco J Herold, W Douglas Fairlie
Journal article | 2019 | Cell Death & Disease
Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort
Gareth Rivalland, Paul Mitchell, Carmel Murone, Khashayer Asadi, Adrienne L Morey, Maud Starmans, Paul C Boutros, Marzena Walkiewicz, Benjamin Solomon, Gavin Wright, Simon Knight, Thomas John
Journal article | 2019 | Translational Lung Cancer Research
A phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE)
Chee Khoon Lee, Antony Mersiades, Jenna Mitchell, Chris Brown, Hannora Jurkovic, Ben Solomon, Thomas John, Martin Stockler, James Chi-Hsin Yang
Conference Proceedings | 2018 | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Yannis Metaxas, Gareth Rivalland, Laetitia A Mauti, Dirk Klingbiel, Steven Kao, Sabine Schmid, Anna K Nowak, Oliver Gautschi, Tammo Bartnick, Brett G Hughes, Hasna Bouchaab, Sacha I Rothschild, Nick Pavlakis, Sibylle Wolleb, Ulf Petrausch, Kenneth O'Byrne, Patrizia Froesch, Melanie Löffler-Baumann, Susanne Pratsch-Peter, Prudence Russell, et al.
Journal article | 2018 | Journal of Thoracic Oncology
INTRODUCTION: There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early..
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Myung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, Sang-We Kim, Jong Seok Lee, Jin-Seok Ahn, Tae Min Kim, Chia-Chi Lin, Hye Ryun Kim, Thomas John, Steven Kao, Jonathan W Goldman, Wu-Chou Su, Ronald Natale, Sarit Rabbie, Bryony Harrop, Philip Overend, Zhenfan Yang, James Chih-Hsin Yang
Journal article | 2017 | The Lancet Respiratory Medicine
BACKGROUND: CNS metastases-including brain and leptomeningeal metastases-from epidermal growth factor receptor (EGFR)-mutant non-s..
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, MV Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert GGM Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, et al.
Journal article | 2017 | Advances In Anatomic Pathology
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
Federica Grosso, Nicola Steele, Silvia Novello, Anna K Nowak, Sanjay Popat, Laurent Greillier, Thomas John, Natasha B Leighl, Martin Reck, Paul Taylor, David Planchard, Jens Benn Sørensen, Mark A Socinski, Ute von Wangenheim, Arsène Bienvenu Loembé, José Barrueco, Nassim Morsli, Giorgio Scagliotti
Journal article | 2017 | Journal of Clinical Oncology
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemo..
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer
Anderly C Chueh, Mun-Sem Liew, Prudence A Russell, Marzena Walkiewicz, Aparna Jayachandran, Maud HW Starmans, Paul C Boutros, Gavin Wright, Stephen A Barnett, John M Mariadason, Thomas John
Journal article | 2017 | Oncotarget
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, MV Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin sss Solomon, Cinzia Solinas, Gert GGM Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, et al.
Journal article | 2017 | Advances In Anatomic Pathology
Treatment of ALK-rearranged non- small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
M Itchins, PL Chia, SA Hayes, VM Howell, AJ Gill, WA Cooper, T John, P Mitchell, M Millward, SJ Clarke, B Solomon, N Pavlakis
Journal article | 2017 | Asia-Pacific Journal of Clinical Oncology
Does access to private healthcare influence potential lung cancer cure rates?
Thadathilankal-Jess John, Dante Plekker, Elvis M Irusen, Coenie FN Koegelenberg
Journal article | 2017 | South African Medical Journal
BACKGROUND: Numerous studies show a link between poor socioeconomic status (SES) and late-stage cancer diagnosis. However, this ha..
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
Bibhusal Thapa, Adriana Salcedo, Xihui Lin, Marzena Walkiewicz, Carmel Murone, Malaka Ameratunga, Khashyar Asadi, Siddhartha Deb, Stephen Arthur Barnett, Simon Knight, Paul Mitchell, D Neil Watkins, Paul C Boutros, Thomas John
Journal article | 2017 | Journal of Thoracic Oncology
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
Licun Wu, Ghassan Allo, Thomas John, Ming Li, Tetsuzo Tagawa, Isabelle Opitz, Masaki Anraku, Zhihong Yun, Melania Pintilie, Bethany Pitcher, Geoffrey Liu, Ron Feld, Michael R Johnston, Marc de Perrot, Ming-Sound Tsao
Journal article | 2017 | Clinical Cancer Research
Purpose: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with few therapeutic options. The tumor-stromal int..
Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens
Natasha Beeton-Kempen, Jessica Duarte, Aubrey Shoko, Jean-Michel Serufuri, Thomas John, Jonathan Cebon, Jonathan Blackburn
Journal article | 2014 | International Journal of Cancer
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP
Min Lu, Hilde Breyssens, Victoria Salter, Shan Zhong, Ying Hu, Caroline Baer, Indrika Ratnayaka, Alex Sullivan, Nicholas R Brown, Jane Endicott, Stefan Knapp, Benedikt M Kessler, Mark R Middleton, Christian Siebold, E Yvonne Jones, Elena V Sviderskaya, Jonathan Cebon, Thomas John, Otavia L Caballero, Colin R Goding, et al.
Journal article | 2013 | Cancer Cell
Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients
Prudence A Russell, Stephen A Barnett, Marzena Walkiewicz, Zoe Wainer, Matthew Conron, Gavin M Wright, Julian Gooi, Simon Knight, Rochelle Wynne, Danny Liew, Thomas John
Journal article | 2013 | Journal of Thoracic Oncology
Medicine - Austin Health